Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients

Hashimoto, Kenji; Engberg, Göran; Shimizu, Eiji; Nordin, Conny; Lindström, Leif H.; Iyo, Masaomi
January 2005
BMC Psychiatry;2005, Vol. 5, p6
Academic Journal
Background: Recent magnetic resonance spectroscopy (MRS) studies report that glutamine is altered in the brains of schizophrenic patients. There were also conflicting findings on glutamate in cerebrospinal fluid (CSF) of schizophrenic patients, and absent for glutamine. This study aims to clarify the question of glutamine and glutamate in CSF of first episode and drug naive schizophrenic patients. Method: Levels of glutamine and glutamate in CSF of 25 first episode and drug-naive male schizophrenic patients and 17 age-matched male healthy controls were measured by a high performance liquid chromatography. Results: The ratio (126.1 (median), 117.7 ã 27.4 (mean ã S.D.)) of glutamine to glutamate in the CSF of patients was significantly (z = -3.29, p = 0.001) higher than that (81.01 (median), 89.1 ã 22.5 (mean ã S.D.)) of normal controls although each level of glutamine and glutamate in patients was not different from that of normal controls. Conclusion: Our data suggests that a disfunction in glutamate-glutamine cycle in the brain may play a role in the pathophysiology of schizophrenia.


Related Articles

  • Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis. Fuente-Sandoval, Camilo de la; León-Ortiz, Pablo; Favila, Rafael; Stephano, Sylvana; Mamo, David; Ramírez-Bermúdez, Jesús; Graff-Guerrero, Ariel // Neuropsychopharmacology;Aug2011, Vol. 36 Issue 9, p1781 

    The glutamatergic and dopaminergic systems are thought to be involved in the pathophysiology of schizophrenia. Their interaction has been widely documented and may have a role in the neurobiological basis of the disease. The aim of this study was to compare, using proton magnetic resonance...

  • Neural Effects of Ziprasidone Monotherapy in First-Episode Schizophrenia: A Longitudinal Study using fMRI and a Procedural Learning Paradigm. Kumari, Veena; Anilkumar, Anantha P. P.; ffytche, Dominic H.; Mehrotra, Ravi; Mitterschiffthaler, Martina T.; Sharma, Tonmoy // Clinical Schizophrenia & Related Psychoses;Jan2008, Vol. 1 Issue 4, p317 

    Introduction: Deficient procedural learning (PL) and lack of striato-thalamic-cortical activity in chronic schizophrenia patients on typical antipsychotics, compared to healthy people, has been previously demonstrated. There is also evidence of striatal dysfunctioning with normal or near-normal...

  • Schizophrenics' Improvement: Maybe It's the New Meds. Or Maybe Not.  // Behavior Analysis Digest International;Spring2008, Vol. 20 Issue 1, p3 

    The article discusses research being done on the effect of second generation antipsychotic drugs on schizophrenic patients. It references study by Terry Goldberg, et al, published in "Archives of General Psychiatry." According to the article, findings suggest that cognitive gains may be due to...

  • Glutamate Level Decreases Significantly in Patients With Secondary Progressive MS. Greb, Erik // Neurology Reviews;Jan2014, Vol. 22 Issue 1, p21 

    A conference paper about decline in glutamate level in secondary progressive multiple sclerosis (MS) patients discussed at the 29th Congress of the European Committee for Treatment and Research in MS (FCTRIMS) is presented. Topics discussed include glutamate and glutamine may result to a loss of...

  • Sudden psychotic episode probably due to meningoencephalitis and Chlamydia pneumoniae acute infection. Xavier, Miguel; Correa, Bernardo; Coromina, Marta; Canas, Nuno; Guimar�es, Jo�o // Clinical Practice & Epidemiology in Mental Health;2005, Vol. 1, p1 

    Background: Since 9% to 20% of all cases of acute psychosis presenting to an Emergency Department (ED) are due to a general medical condition, cautious medical workup should be mandatory in such patients. Differential diagnosis must consider conditions as diverse as renal failure or CNS...

  • Association between Characteristics of Brain Magnetic Resonance Imaging and Atypical Antipsychotics Use in Dementia Patients. Jongtaek Choi; Jiwon Kim; Yangho Roh; Sukhwan Rhu; Sungil Woo; Sangwoo Hahn; Jaeuk Hwang // Korean Journal of Biological Psychiatry;2013, Vol. 20 Issue 3, p97 

    Objectives We aimed to identify the neuroimaging marker for prediction of the use of atypical antipsychotics (AAP) in dementia patients. Method From April 2010 to March 2013, 31 patients who were diagnosed as dementia at the psychiatric department of Soonchunhyang University Hospital, completed...

  • Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia. Holmes, Elaine; Tsang, Tsz M.; Huang, Jeffrey T.-J.; Leweke, F. Markus; Koethe, Dagmar; Gerth, Christoph W.; Nolden, Brit M.; Gross, Sonja; Schreiber, Daniela; Nicholson, Jeremy K.; Bahn, Sabine // PLoS Medicine;Aug2006, Vol. 3 Issue 8, pe327 

    Background:The identification of schizophrenia biomarkers is a crucial step towards improving current diagnosis, developing new presymptomatic treatments, identifying high-risk individuals and disease subgroups, and assessing the efficacy of preventative interventions at a rate that is not...

  • Metabotropic glutamate receptor agonists for schizophrenia. Harrison, Paul J. // British Journal of Psychiatry;Feb2008, Vol. 192 Issue 2, p86 

    A drug acting at metabotropic glutamate receptors has recently been reported to be an effective antipsychotic, breaking the rule that only dopamine receptor-blocking drugs have this property. The finding complements accumulating evidence that glutamatergic abnormalities are important in the...

  • Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia. Egerton, Alice; Brugger, Stefan; Raffin, Marie; Barker, Gareth J; Lythgoe, David J; McGuire, Philip K; Stone, James M // Neuropsychopharmacology;Oct2012, Vol. 37 Issue 11, p2515 

    Many patients with schizophrenia show a limited symptomatic response to treatment with dopaminergic antipsychotics. This may reflect the additional involvement of non-dopaminergic neurochemical dysfunction in the pathophysiology of the disorder. We tested the hypothesis that brain glutamate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics